Tech Company Financing Transactions
GlobeImmune Funding Round
GlobeImmune closed a $38.4 million Series B funding round on 1/10/2006. Investors included Lilly Ventures, Adams Harkness Ventures and Biogen Idec.
Transaction Overview
Company Name
Announced On
1/10/2006
Transaction Type
Venture Equity
Amount
$38,400,000
Round
Series B
Investors
Proceeds Purpose
The Company plans to use the Series B funds to complete a placebo-controlled Phase 2 clinical trial of GI-4000 in patients with pancreatic cancer as well as complete a placebo-controlled Phase 1b clinical trial of GI-5005 in patients with chronic hepatitis C infection.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1450 Infinite Dr.
Louisville, CO 80027
USA
Louisville, CO 80027
USA
Phone
Website
Email Address
Overview
GlobeImmune is developing Tarmogen product candidates to treat cancer and infectious diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Timothy Rodell
VP - Bus. Development
Kirk Christoffersen
VP - Finance
Jeffrey Dekker
Browse more venture capital transactions:
Prev: 1/10/2006: Azure Communications venture capital transaction
Next: 1/10/2006: SilverStorm Technologies venture capital transaction
Share this article
News on VC Transactions
We document all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs